PF-05280014 demonstrated equivalence in objective response rate to Herceptin after 25 weeks of treatment in first line patients with HER2-positive metastatic breast cancer. The Reflections B3271002 is a
The company's decision follows the start of phase 3 clinical trial of the Tetravalent Immunization against Dengue Efficacy Study (TIDES), the global phase 3 clinical trial to assess the efficacy of a
Accucaps develops and manufactures over-the-counter (OTC), high potency and conventional pharmaceutical softgels. The companies did not disclose the financial details of the transaction, which is subject to approval from the Canadian
Merck is seeking approval of Keytruda at a fixed dose of 200 mg every 3 weeks. The application includes data from five uncontrolled, open-label, multicohort, multisite phase I/II
Earlier, NICE did not recommend ibrutinib, also known as Imbruvica, for routine National Health Service (NHS use). After a reduction in price, the independent appraisal committee approved the
The US healthcare firm said there can be no assurance any transaction will be signed from the preliminary negotiations. It also noted that further comments regarding the discussions
Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). The phase III programme includes two studies assessing the safety and efficacy of daprodustat compared to recombinant human erythropoietin.
ORI Healthcare Fund (ORI Fund) led the Series C financing with participation by Shenzhen Hepalink Pharmaceutical (Hepalink). Existing shareholders Wellcome Trust, Bill & Melinda Gates Foundation, Malin Corporation,
EGPA is a rare disease in which patients suffer from inflammation that is widespread in the walls of small blood vessels. The treatment aims is to induce and
The US Food and Drug Administration (FDA) has now lifted the partial clinical hold preventing enrolment of new patients with head and neck squamous cell carcinoma (HNSCC) in clinical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.